Investigational drug · Phase 2
BLB-201
Also called: PIV5-vectored RSV Vaccine
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Respiratory Syncytial Virus Infections.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BLB-201"
First trial start
2023
Mar 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BLB-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Respiratory Syncytial Virus Infections
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BLB-201" as an intervention, largest first.
- A Study of BLB-201 RSV Vaccine in Infants and ChildrenPivotal-lookingRecruiting
Blue Lake Biotechnology Inc.Industry
NCT05655182 · 137 participants (planned) · Start Mar 9, 2023 · Primary completion Dec 30, 2028
Drug: PIV5-vectored RSV Vaccine (BLB-201) Low Dose; PIV5-vectored RSV Vaccine (BLB-201) High Dose and 1 more · For: Respiratory Syncytial Virus Infections
Sites: La Mesa, California; Modesto, California; San Diego, California · 18 sites in all
Blue Lake Biotechnology Inc.Industry
NCT05281263 · 30 participants · Start Jul 20, 2022 · Primary completion Dec 5, 2022
Drug: CPI-RSV-F Vaccine (BLB-201) · For: Respiratory Syncytial Virus Infections
Sites: Cincinnati, Ohio; North Charleston, South Carolina
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Respiratory Syncytial Virus Infections
- RSVPreF3 OA investigational vaccinePhase 33 trials
GSK · Respiratory Syncytial Virus Infections
- RSVPreF3 OA vaccinePhase 32 trials
GSK · Respiratory Syncytial Virus Infections
- TNM001Phase 32 trials
Zhuhai Trinomab Pharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections
- ZiresovirAK0529Phase 32 trials
Shanghai Ark Biopharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections, Respiratory Synctial Virus Infections
- Adjuvanted RSVPreF3 vaccinePhase 22 trials
GSK · Cardiovascular Disease, Respiratory Syncytial Virus Infections
- SYH2066Phase 21 trial
CSPC Ouyi Pharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.